Načítá se...
Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
BACKGROUND: Cetuximab and panitumumab are monoclonal antibodies targeting the epidermal growth factor receptor. Both drugs are active against RAS wild type metastatic colorectal cancer after chemotherapy failure, with similar efficacy and toxicity profiles. However, their cost and limited survival b...
Uloženo v:
| Vydáno v: | PLoS One |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Public Library of Science
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5389795/ https://ncbi.nlm.nih.gov/pubmed/28403233 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0175409 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|